Pharmaceuticals, Biotechnology and Life Sciences
Probi AB has appointed Jörn Andreas as CFO. Andreas will replace Niklas Brandt who will remain in Probis leadership team as CIO with responsibility for IT infrastructure and Investor relations.
The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry.
ViiV Healthcare, majority-owned by GSK, with Pfizer and Shionogi Limited as shareholders, has announced detailed study results from its phase III programme evaluating the safety and efficacy of switching virologically suppressed patients from a three- or four-drug antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC).
Horizon Discovery Group has sign a Master Services Agreement with its largest customer, which will be a template for increasing revenue for about £2 million in 2017.
Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
Gilead Sciences will present findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment, at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Allergan has made another acquisition deal in expanding its medical aesthetics portfolio by buying Zeltiq Aesthetics for $2.475 billion.
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointed Peter Donhauser, D.O. to its Board of Directors.
The global pharmaceutical grade silica gel market is projected to reach a market size of $71.05 million by 2025.
Acacia Pharma Group has made final pivotal Phase 3 study testing amisulpride injection Baremsis, formerly APD421, for patients with post-operative nausea & vomiting (PONV), after getting antiemetic prophylaxis, and now all phases met primary endpoints.